Rejuvel Bio-Sciences, Inc.
NUUU
$0.00
$0.000.00%
| 09/30/2015 | 06/30/2015 | 03/31/2015 | 12/31/2014 | 09/30/2014 | |
|---|---|---|---|---|---|
| Revenue | 173.91% | -16.24% | 2,960.87% | 93.63% | 327.91% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 173.91% | -16.24% | 2,960.87% | 93.63% | 327.91% |
| Cost of Revenue | 5,000.00% | -18.33% | 217.24% | 256.73% | 116.67% |
| Gross Profit | 120.88% | -15.63% | 8,842.86% | -776.00% | 230.91% |
| SG&A Expenses | 30.83% | 272.54% | 111.42% | 3.70% | 171.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.61% | 262.11% | 113.75% | 28.78% | 176.05% |
| Operating Income | -22.33% | -357.86% | -63.06% | -23.53% | -167.13% |
| Income Before Tax | -286.93% | -136.70% | 89.75% | 163.48% | 213.47% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -286.93% | -136.70% | 89.75% | 163.48% | 213.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -286.93% | -136.70% | 89.75% | 163.48% | 213.47% |
| EBIT | -22.33% | -357.86% | -63.06% | -23.53% | -167.13% |
| EBITDA | -22.19% | -360.97% | -62.95% | -22.95% | -168.78% |
| EPS Basic | -500.00% | -186.11% | 75.86% | 255.00% | 223.08% |
| Normalized Basic EPS | -500.00% | -185.56% | 76.38% | 246.15% | 225.00% |
| EPS Diluted | -725.00% | -224.00% | 75.86% | 255.00% | 223.08% |
| Normalized Diluted EPS | -500.00% | -186.52% | 76.38% | 246.15% | 225.00% |
| Average Basic Shares Outstanding | -52.14% | -57.21% | -57.32% | -59.04% | -9.43% |
| Average Diluted Shares Outstanding | -52.17% | -57.65% | -57.32% | -59.04% | -9.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
